Watson Pharmaceuticals

In a report published by Morgan Stanley, Mylan is seeking FDA approval of generic Lipitor in June 2011 for Watson Pharmaceuticals (NYSE: WPI). Morgan Stanley said that Mylan is suing FDA to deny Ranbaxy's 180 days of marketing exclusivity on generic Lipitor. “If FDA denies Ranbaxy's exclusivity,...

Citigroup has published a research report on Watson Pharmaceuticals (NYSE: WPI) after the company's participation in Citi's Healthcare conference. In the report, Citigroup writes "Paul Bisaro, WPI's President & CEO reiterated WPI's 2011 diluted EPS target of $3.85 to $4.15 and revenue of $4.2B...

According to J.P. Morgan, Watson Pharmaceuticals (NYSE: WPI) reported it is modestly adjusting its model following Watson's release of its 2010 Form 10-K, but not changing its revenue or EPS assumptions. J.P. Morgan reported that Watson trades at roughly 13.7x our 2011 cash EPS estimate of $4.14,...

Morgan Stanley is out with its report today on Watson Pharmaceutical (NYSE: WPI), raising its price target from $61 to $63. In a note to clients, Morgan Stanley writes, "4Q results were essentially in line, and management reaffirmed 2011 guidance given at the January 21 Investor Day. We have...

Morgan Stanley announced this morning that it is initiating coverage on shares of Watson Pharmaceuticals, Inc. (NYSE: WPI) with an Overweight rating and $61 target. “Our detailed valuation indicates that the Street may be underestimating the magnitude and durability of Concerta cash flows,” Morgan...

Yesterday, Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that it entered into an exclusive agreement with Johnson & Johnson (NYSE: JNJ) to distribute an authorized generic (AG) version of Concerta beginning on May 1, 2011, Piper Jaffray reports. The economics surrounding the agreement will...

The announced agreement for an authorized Concerta generic between Johnson & Johnson (NYSE: JNJ) and Watson Pharmaceuticals, Inc. (NYSE: WPI) brings Concerta generic earlier than anticipated, Piper Jaffray reports. “However, by our analysis, the impact on JNJ's earnings will be relatively...

Argus has upgraded Watson Pharmaceuticals (NYSE: WPI) from Hold to Buy with a $51 price target.

Watson Pharmaceuticals, Inc. (NYSE: WPI) on Tuesday reported a 4th quarter profit of $56.9 million, or 51 cents per share, up from $56.4 million, or 50 cents per share, a year earlier. On an adjusted cash basis, Watson Pharmaceuticals' profit was 85 cents per share, while net revenue rose 22% to $...